News & Analysis on Clinical Trial Services & Contract Research And Development
The budget committee of Italy's Lower House of Parliament has approved a plan by the opposition to require the national medicines agency, the AIFA, to draw up a method of establishing 'optimal' packaging for drugs to treat major diseases, reports the...
Singapore-based biologics contract manufacturer, A-Bio Pharma has won its first contract after entering into a process development and clinical supply service agreement with GlaxoSmithKline's vaccine division, GlaxoSmithKline Biologicals.
Researchers have used engineered stem cells to zero in on tumours to become part of the supporting tissue. They can then act as vehicles for drugs that are pumped into the cancer, sparing normal tissue.
The shrink sleeve label is a staple of the food and beverage industry, but has not been widely adopted for pharmaceutical use. However, this could change as the technology has child-resistance properties that could be of value in packaging drugs.
MatriCal has introduced its SonicMan sonication system to the European compound management market with versions that can handle 384- as well as 96-well microwell plate formats.
Dow Chemical has renewed a collaboration with the University of Texas at Austin (UT Austin) in the US aimed at developing a new technology to improve the solubility and bioavailability of candidate drugs.
According to a report, it takes 7-10 years to develop and market a drug with costs exceeding $800 million (€625 million). This revelation is set to add to the pressure already facing pharmaceutical and biotechnology companies which are already...
Agilent Technologies has launched what it claims is the industry's first fully automated, high-throughput 'lab-on-a-chip system' for basic life science research and drug discovery. The Agilent 5100 Automated provides unattended analysis of thousands...
A one-dose, microsphere formulation of azithromycin is as effective as several days' treatment with other drugs for respiratory tract infections (RTIs), according to new clinical data.
UK company MicroScience has completed a Phase I study of a new therapeutic vaccine for patients carrying the hepatitis B virus, raising the hope of a new approach to tackling this life-threatening infection.